Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposiu...
September 15 2016 - 7:30AM
Business Wire
The NYAS’ 13th Key Symposium 2016: Bioelectronic Medicine –
Technology Targeting Molecular Mechanisms brings together thought
leaders to advance this growing frontier of patient care
Novocure (NASDAQ: NVCR) announced today that Executive Chairman
William Doyle will present at the New York Academy of Sciences’
13th Key Symposium 2016: Bioelectronic Medicine – Technology
Targeting Molecular Mechanisms on Friday, Sept. 23, 2016. Mr.
Doyle’s presentation “Tumor Treating Fields – A Novel Cancer
Therapy Utilizing Alternating Electric Fields” will focus on
Novocure’s innovative treatment for solid tumors.
The symposium brings together thought leaders of bioelectronic
medicine, which NYAS describes as the epicenter of where
healthcare, technology and science converge and a science that may
change the future of therapies for a wide variety of diseases.
“I am honored to share the science of Tumor Treating Fields
(TTFields) at this prestigious event,” Mr. Doyle said. “Treatment
with TTFields significantly prolongs survival of patients with
newly diagnosed glioblastoma without the cancer therapy side
effects that commonly compromise quality of life. We are committed
to bringing TTFields therapy to GBM patients and to advancing our
clinical pipeline in other solid tumor cancers.”
About Novocure
Novocure is a commercial-stage oncology company developing a
novel, proprietary therapy called Tumor Treating Fields, or
TTFields, for the treatment of solid tumor cancers. Headquartered
in Jersey, Novocure has U.S. operations
in Portsmouth, New Hampshire, Malvern, Pennsylvania,
and New York City. Additionally, the company has offices
in Germany, Switzerland and Japan, and a
research center in Haifa, Israel. For additional information
about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe" or other words and terms of similar meaning.
Novocure's performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on March 1, 2016, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160915005067/en/
Media and Investor Contact:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Sep 2023 to Sep 2024